Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 11.21
CEMP's Cash to Debt is ranked lower than
57% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. CEMP: 11.21 )
Ranked among companies with meaningful Cash to Debt only.
CEMP' s 10-Year Cash to Debt Range
Min: 1.12  Med: 7.12 Max: No Debt
Current: 11.21
Equity to Asset 0.82
CEMP's Equity to Asset is ranked higher than
68% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CEMP: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
CEMP' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.67 Max: 0.82
Current: 0.82
0.48
0.82
F-Score: 5
Z-Score: 19.98
M-Score: -0.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -228.82
CEMP's Operating margin (%) is ranked lower than
63% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. CEMP: -228.82 )
Ranked among companies with meaningful Operating margin (%) only.
CEMP' s 10-Year Operating margin (%) Range
Min: -549.34  Med: -469.86 Max: -390.38
Current: -228.82
-549.34
-390.38
Net-margin (%) -237.76
CEMP's Net-margin (%) is ranked lower than
64% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. CEMP: -237.76 )
Ranked among companies with meaningful Net-margin (%) only.
CEMP' s 10-Year Net-margin (%) Range
Min: -576.41  Med: -490.79 Max: -405.16
Current: -237.76
-576.41
-405.16
ROE (%) -82.23
CEMP's ROE (%) is ranked lower than
76% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CEMP: -82.23 )
Ranked among companies with meaningful ROE (%) only.
CEMP' s 10-Year ROE (%) Range
Min: -94.12  Med: -82.32 Max: -70.51
Current: -82.23
-94.12
-70.51
ROA (%) -54.23
CEMP's ROA (%) is ranked lower than
72% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. CEMP: -54.23 )
Ranked among companies with meaningful ROA (%) only.
CEMP' s 10-Year ROA (%) Range
Min: -191.64  Med: -60.35 Max: -53.06
Current: -54.23
-191.64
-53.06
ROC (Joel Greenblatt) (%) -5452.99
CEMP's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. CEMP: -5452.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CEMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -47405.52  Med: -36528.00 Max: -18139.82
Current: -5452.99
-47405.52
-18139.82
EBITDA Growth (3Y)(%) -64.50
CEMP's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. CEMP: -64.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CEMP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.6  Med: -65.90 Max: -64.5
Current: -64.5
-67.6
-64.5
EPS Growth (3Y)(%) -66.40
CEMP's EPS Growth (3Y)(%) is ranked lower than
98% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CEMP: -66.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CEMP' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.3  Med: -68.00 Max: -66.4
Current: -66.4
-69.3
-66.4
» CEMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CEMP Guru Trades in Q3 2013

First Eagle Investment 1,308,701 sh (unchged)
» More
Q4 2013

CEMP Guru Trades in Q4 2013

First Eagle Investment 780,275 sh (-40.38%)
» More
Q1 2014

CEMP Guru Trades in Q1 2014

First Eagle Investment Sold Out
» More
Q1 2015

CEMP Guru Trades in Q1 2015

Paul Tudor Jones 15,611 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.13
CEMP's P/B is ranked lower than
70% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. CEMP: 8.13 )
Ranked among companies with meaningful P/B only.
CEMP' s 10-Year P/B Range
Min: 2.35  Med: 7.67 Max: 19.48
Current: 8.13
2.35
19.48
P/S 48.04
CEMP's P/S is ranked lower than
72% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. CEMP: 48.04 )
Ranked among companies with meaningful P/S only.
CEMP' s 10-Year P/S Range
Min: 22.55  Med: 46.69 Max: 73.6
Current: 48.04
22.55
73.6
EV-to-EBIT -21.58
CEMP's EV-to-EBIT is ranked lower than
465% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. CEMP: -21.58 )
Ranked among companies with meaningful EV-to-EBIT only.
CEMP' s 10-Year EV-to-EBIT Range
Min: -25.2  Med: -6.90 Max: -3.1
Current: -21.58
-25.2
-3.1
Current Ratio 13.32
CEMP's Current Ratio is ranked higher than
83% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CEMP: 13.32 )
Ranked among companies with meaningful Current Ratio only.
CEMP' s 10-Year Current Ratio Range
Min: 2.48  Med: 10.18 Max: 30.34
Current: 13.32
2.48
30.34
Quick Ratio 13.32
CEMP's Quick Ratio is ranked higher than
83% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CEMP: 13.32 )
Ranked among companies with meaningful Quick Ratio only.
CEMP' s 10-Year Quick Ratio Range
Min: 2.48  Med: 10.18 Max: 30.34
Current: 13.32
2.48
30.34
Days Sales Outstanding 198.86
CEMP's Days Sales Outstanding is ranked lower than
90% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. CEMP: 198.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMP' s 10-Year Days Sales Outstanding Range
Min: 56.37  Med: 66.17 Max: 75.96
Current: 198.86
56.37
75.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.95
CEMP's Price/Net Cash is ranked higher than
51% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. CEMP: 8.95 )
Ranked among companies with meaningful Price/Net Cash only.
CEMP' s 10-Year Price/Net Cash Range
Min: 2.64  Med: 4.53 Max: 15.37
Current: 8.95
2.64
15.37
Price/Net Current Asset Value 8.14
CEMP's Price/Net Current Asset Value is ranked higher than
51% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. CEMP: 8.14 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CEMP' s 10-Year Price/Net Current Asset Value Range
Min: 2.62  Med: 4.46 Max: 13.91
Current: 8.14
2.62
13.91
Price/Tangible Book 8.12
CEMP's Price/Tangible Book is ranked lower than
61% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CEMP: 8.12 )
Ranked among companies with meaningful Price/Tangible Book only.
CEMP' s 10-Year Price/Tangible Book Range
Min: 2.61  Med: 4.44 Max: 13.83
Current: 8.12
2.61
13.83
Price/Median PS Value 1.07
CEMP's Price/Median PS Value is ranked higher than
59% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. CEMP: 1.07 )
Ranked among companies with meaningful Price/Median PS Value only.
CEMP' s 10-Year Price/Median PS Value Range
Min: 0.53  Med: 0.98 Max: 1.17
Current: 1.07
0.53
1.17
Earnings Yield (Greenblatt) (%) -4.54
CEMP's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CEMP: -4.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CEMP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -6.6  Med: 0.00 Max: 0
Current: -4.54
-6.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:9C1.Germany,
Cempra Inc is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. The Company is a clinical-stage pharmaceutical company which is engaged in the development of differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's main product, solithromycin (CEM-101), is in Phase 3 clinical trials. The Company is developing solithromycin in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP. Solithromycin is a potent new fourth generation macrolide and the first fluoroketolide in clinical development. The Company is also completed a Phase 2 study of solithromycin in uncomplicated gonorrhea. Its second program is Taksta, which the Company is developing in the U.S. as a long term oral treatment for prosthetic joint infections caused by staphylococci, including S. aureus and MRSA. The Company is conducting a Phase 2 trial for Taksta in patients with prosthetic joint infections and have submitted a proposal for a Phase 3 trial for Tasksta as a treatment for PJI. The Company has licensed solithromycin to Toyama Chemical Co., Ltd. for development and commercialization in Japan while retaining the rights to the rest of the world. The Company is developing Taksta in the U.S. as a long term oral treatment of prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus, or MRSA.
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
Does Cempra Have The Next Blockbuster Drug? Jan 08 2015 

More From Other Websites
More Than 60% Returns For These Two Hedgies’ Favorite Health Care Picks Jun 24 2015
SunTrust's 5 Biotech Picks For The Next 6 Months Jun 17 2015
Five Biotech Stocks for the Next Six Months Jun 17 2015
Cempra to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
CEMPRA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
Aisling Capital Reduces Stake in Cempra Inc (CEMP) May 21 2015
Cempra Presenting Additional Data From the Phase 3 Oral Solithromycin Study in Community Acquired... May 19 2015
Cempra to Present Solithromycin Data at Two Upcoming Medical Conferences May 12 2015
2 Biotech Buyout Candidates as Antibiotics Stop Working May 04 2015
Busted biotechs: by the numbers Apr 30 2015
Cempra reports 1Q loss Apr 30 2015
Cempra reports 1Q loss Apr 30 2015
Cempra Inc Earnings Call scheduled for 4:30 pm ET today Apr 30 2015
CEMPRA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 30 2015
Cempra Reports First Quarter 2015 Financial Results and Provides Corporate Update Apr 30 2015
Q1 2015 Cempra Inc Earnings Release - After Market Close Apr 30 2015
Japanese patent to infuse $10M into Chapel Hill drug developer Apr 27 2015
CEMPRA, INC. Files SEC form 8-K, Other Events Apr 24 2015
Cempra to Report First Quarter 2015 Financial Results Apr 23 2015
Cempra to Present at Two Upcoming Scientific Conferences Apr 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK